1. Home
  2. NWGL vs BLRX Comparison

NWGL vs BLRX Comparison

Compare NWGL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nature Wood Group Limited

NWGL

Nature Wood Group Limited

HOLD

Current Price

$0.60

Market Cap

12.1M

Sector

N/A

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

N/A

Current Price

$3.00

Market Cap

12.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NWGL
BLRX
Founded
2008
2003
Country
Macau
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
12.0M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
NWGL
BLRX
Price
$0.60
$3.00
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
3.0M
6.8K
Earning Date
05-21-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$2.15
52 Week High
$1.82
$4.56

Technical Indicators

Market Signals
Indicator
NWGL
BLRX
Relative Strength Index (RSI) 75.48 53.64
Support Level $0.19 $2.64
Resistance Level $1.46 $3.07
Average True Range (ATR) 0.09 0.21
MACD 0.04 0.03
Stochastic Oscillator 74.59 61.64

Price Performance

Historical Comparison
NWGL
BLRX

About NWGL Nature Wood Group Limited

CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: